You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2024

CLINICAL TRIALS PROFILE FOR PRIMIDONE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Primidone

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00006025 ↗	Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma	Completed	National Cancer Institute (NCI)	Phase 1	2001-01-05	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of temozolomide plus irinotecan in treating patients who have recurrent malignant glioma.
NCT00006025 ↗	Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma	Completed	North American Brain Tumor Consortium	Phase 1	2001-01-05	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of temozolomide plus irinotecan in treating patients who have recurrent malignant glioma.
NCT00006025 ↗	Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma	Completed	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 1	2001-01-05	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of temozolomide plus irinotecan in treating patients who have recurrent malignant glioma.
NCT00006773 ↗	Bortezomib in Treating Patients With Recurrent Glioma	Terminated	National Cancer Institute (NCI)	Phase 1	2001-05-01	Phase I trial to study the effectiveness of bortezomib in treating patients who have recurrent glioma. Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth
NCT00068770 ↗	Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT	Terminated	National Cancer Institute (NCI)	Phase 2	2003-10-01	RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Primidone

Condition Name

Chart
Table

Condition Name for Primidone
Intervention	Trials
Essential Tremor	5
Epilepsies, Partial	5
Seizures	5
Epilepsy	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Primidone
Intervention	Trials
Tremor	7
Essential Tremor	6
Seizures	5
Epilepsy	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Primidone

Trials by Country

Map
Table

Trials by Country for Primidone
Location	Trials
United States	35
Hungary	2
India	1
France	1
Netherlands	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Primidone
Location	Trials
North Carolina	4
Maryland	4
New York	3
Massachusetts	3
California	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Primidone

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Primidone
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	5
Phase 2	12
[disabled in preview]	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Primidone
Clinical Trial Phase	Trials
Completed	16
Withdrawn	3
Terminated	2
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Primidone

Sponsor Name

Chart
Table

Sponsor Name for Primidone
Sponsor	Trials
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	6
National Cancer Institute (NCI)	4
Duke University	2
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Primidone
Sponsor	Trials
Other	21
Industry	16
NIH	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.